Table 2.
Summary of affinity methods – kinases
| Protein target | |||||||
|---|---|---|---|---|---|---|---|
| Protein kinases | Drug/inhibitor analogues | Compound class | Affinity method | Separation method | Detection method/MS | Identified proteins | Reference |
| CDKs (ser/thr-specific) | purvalanol | 2,6,9-tri-substituted purine | PAC | SDS-PAGE | microsequencing | 9 protein kinases | (Knockaert et al., 2000) |
| CDKs/KSK-3 (ser/thr-specific) | paullones | PAC | SDS-PAGE | microsequencing | GSK-3α, GSK-3β, MDHM | (Knockaert et al., 2002) | |
| CDK2 (ser/thr-specific) | PHA-539136 | cyclopropylpyrazole | PAC | SDS-PAGE/2D PAGE | MALDI MS | Cdk2, HSP-90α, 90β, 78, 70, 27, enolase, tubulin–β chain | (Lolli et al., 2003) |
| CDK2 (ser/thr-specific) | (R)-Roscovitine | pegylated roscovitine | PAC | SDS-PAGE | MALDI MS, Western blotting | (Bach et al., 2005) | |
| p38/MAPK family | SB 203580 | pyridinyl imidazole | PAC | 16-BAC/SDS-PAGE | MALDI MS | (Godl et al., 2003) | |
| PKC family (ser/thr-specific) | GF109203X (BisI) | bisindolylmaleimide | PAC | 16-BAC/SDS-PAGE | MALDI MS | 17 protein kinases | (Brehmer et al., 2004) |
| PKCα family | BisIII | bisindolylmaleimide | PAC /SAC | IAP, SDS-PAGE | ESI IT MS/MS | PKC-R, GSK3-β, CaMKII, adenosine kinase, CDK2 | (Saxena et al., 2008) (Saxena et al., 2009) |
| Bcr-Abl (tyr-specific) | PD180970/PP58 | pyrido[2,3,-d]pyrimidine | PAC | 16-BAC/SDS-PAGE | MALDI MS/ESI Q-TOF MS | 35 protein kinases | (Wissing et al., 2004) |
| Bcr-Abl (tyr-specific) | imatinib, nilotinib, dasatinib, INNO-406 | 2-phenylamino pyrimidine | PAC | SDS-PAGE | ESI Q-TOF MS | multiple kinases | (Rix et al., 2007) (Rix et al., 2011) (Li et al., 2010) |
| EGFR (tyr-specific) | Gefitinib/AX14596 | PAC | 16-BAC/SDS-PAGE | MALDI MS | 20 protein kinases | (Brehmer et al., 2005) | |
| PDGFR, VEGFR2 (tyr-specific) | SU6668 | indolinone | PAC | 16-BAC/SDS-PAGE | MALDI MS | 8 protein kinases | (Godl et al., 2005) |
| Jurkat, HCT-116, A549 cell kinomes | multiple | PAC | SDS-PAGE | ESI Q-TOF MS | 140 protein kinases | (Wissing et al., 2007) | |
| HeLa S3 S- and M- phase kinomes | multiple | PAC | SDS-PAGE, Mudpit | SILAC, LTQ-Orbitrap MS | 219 protein kinases | (Daub et al., 2008) | |
| MV4–11 leukaemia, HCT116, MDA-MB-435S kinomes | VI16741/VI16743/VI16832 | pyrido[2,3,-d]pyrimidine | PAC | SDS-PAGE | SILAC, LTQ-Orbitrap MS | 200 protein kinases | (Oppermann et al., 2009) |
| Multiple mouse and human cell lines and primary tissues | multiple | PAC | iTRAQ, LTQ-Orbitrap MS | 307 protein kinases | (Bantscheff et al., 2007) | ||
| CLL cells | multiple | PAC | iTRAQ, LTQ-Orbitrap MS | multiple kinases | (Kruse et al., 2011) | ||
| HepG2 hepatocarcinoma, human placenta | staurosporine | azido, biotin | SAC | Streptavidin chromatography | LTQ-Orbitrap MS | 100 kinases | (Fischer et al., 2010) |
IAP. immuno affinity purification.